Bli medlem
Bli medlem

Du är här


CombiGene: University of Copenhagen has become new shareholder

Following a share transfer from CombiGene's co-founder David Woldbye,
the University of Copenhagen is now a shareholder in CombiGene, with
1.9% of the shares. The transaction is based on a mutual agreement
from 2007.

The University of Copenhagen has become a shareholder in CombiGene and
now holds 216 000 shares. The transfer fulfils an agreement dating
back to a PCT patent application from 2007, which stipulated that the
transfer would be conducted once CombiGene became a public and listed

"We are proud to have the distinguished University of Copenhagen as a
shareholder", says CombiGene's Chairman Arne Ferstad and continues
"It also reflects the value in the ongoing Swedish-Danish

After the transaction was executed on January 12th 2016, University of
Copenhagen owns 1.9% of the shares in CombiGene and David Woldbye
owns 1.9%.

For further information:

CombiGene AB (publ)

Bengt Westrin, CEO

Tel: +46 70 265 48 62


About University of Copenhagen

The University of Copenhagen is the largest university in Denmark and
recognised as one of Europe's leading universities. Six faculties and
the Biotech Research and Innovation Centre (BRIC) constitute the
backbone of the University and the intellectual playground for 5,500
researchers and 40,000 students. The University of Copenhagen is
ranked no 7 in Europe on the Leiden Ranking 2015 and is on the Top 50
list of institutions publishing articles in Nature and Science

About CombiGene AB

By combining modern neuroscience with recent advances in gene
delivery, CombiGene has developed a method shown to suppress
epileptic seizures in preclinical studies. The current focus is on
continuing to develop this method into an effective and safe therapy
for epilepsy patients, but the method may also have development
potential as a means of treating other neurological disorders.
Founded on the basis of scientific discoveries made at Lund
University and the University of Copenhagen, CombiGene has offices at
Medicon Village in Lund, Sweden. The company is public and listed on
the Swedish marketplace AktieTorget.

Please also read MORE FROM THE COMPANY, a newsletter from CombiGene
which contains general news and information that is judged not to
have a significant effect on the share price. Other issues of MORE


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.